fbpx
CAS Insight

molecules of the month

CHF-6366

inhaled mAChRs and ADRB2 agonist

Ph. I/II candidate in Asthma and COPD discontinued

soft drug design from previously disclosed lead MABA

J. Med. Chem.

Chiesi Farmaceutici S.p.A, Parma, IT

CHF-6366 Chemical Structure inhaled mAChRs and ADRB2 agonist - Chiesi Farmaceutici S.p.A, Parma, IT
5 mins read

Context. CHF-6366 (Chiesi Farmaceutici S.p.A) is a muscarinic antagonist and β2 agonist (MABA) being developed as an inhaled treatment for respiratory diseases. Muscarinic antagonists and β2 agonists both act to inhibit bronchoconstriction, but through different mechanisms, making the combination of both agents a desirable strategy for achieving enhanced efficacy in treating pulmonary diseases. Although long-acting formulations of muscarinic antagonists and β2 agonists have been combined and used actively in the last 10 years (e.g., Anoro Ellipta and Stiolto Respimat), various drawbacks associated with such multicomponent inhalers have led to efforts to develop bifunctional agents with dual activity on either receptor. Such MABAs are expected to be single molecular entities comprising two covalently-linked pharmacophores. At least 5 MABA agents are currently…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: